Absolute Quantification of Four Isoforms of the Class I Phosphoinositide-3-kinase Catalytic Subunit by Real-Time RT-PCR

Access this Article

Author(s)

Abstract

Class I phosphoinositide-3-kinase (PI3K) consists of four isoforms of the catalytic subunit, p110α, -β, -δ and -γ, generated from the genes PIK3CA, -B, -D and -G, respectively. These isoforms show different tissue distribution and some specific and indispensable functions in various biological pathways such as development, inflammation, autoimmunity and malignancy. In human cancers, frequent genomic amplification and gain-of-function mutations of PIK3CA were reported, which suggests an oncogenic potential. However, the role played by the other three isoforms in human cancer remains to be determined. We wanted to investigate the relationship between all the isoforms in human cancers. Here, we have established a system for the simultaneous absolute-quantification of all four isoforms by real-time reverse transcription polymerase chain reaction (RT-PCR). The reliability of this system was confirmed using three main criteria: (i) good correlation of each standard curve, (ii) high specificity of the PCR reactions and (iii) excellent reproducibility. Using this system, we investigated human monocytic leukemia cells (U937) to analyze expression of all four isoforms. The biological implications of the expression level of the four isoforms of class I PI3K catalytic subunit are discussed.

Journal

  • Biological and Pharmaceutical Bulletin

    Biological and Pharmaceutical Bulletin 30(6), 1181-1184, 2007-06-01

    The Pharmaceutical Society of Japan

References:  44

  • <no title>

    HAWKINS P. T.

    Biochem. Soc. Trans. 34, 647-662, 2006

    Cited by (1)

  • <no title>

    SHAW R. J.

    Nature (London) 441, 424-430, 2006

    Cited by (1)

  • <no title>

    FRESNO VARA J. A.

    Cancer Treat. Rev. 30, 193-204, 2004

    Cited by (1)

  • <no title>

    DANCEY J. E.

    Cancer Biol. Ther. 5, 1065-1073, 2006

    Cited by (1)

  • <no title>

    CULLY M.

    Nat. Rev. Cancer 6, 184-192, 2006

    Cited by (1)

  • <no title>

    LESLIE N. R.

    Biochem. J. 382, 1-11, 2004

    Cited by (1)

  • <no title>

    KIM R. H.

    Br. J. Cancer 94, 620-624, 2006

    Cited by (1)

  • <no title>

    KARAKAS B.

    Br. J. Cancer 94, 455-459, 2006

    Cited by (1)

  • <no title>

    SAMUELS Y.

    Science 304, 554, 2004

    Cited by (1)

  • <no title>

    DOS SANTOS C.

    Bull. Cancer 93, 445-447, 2006

    Cited by (1)

  • <no title>

    STEPHENS L.

    Curr. Opin. Pharmacol. 5, 357-365, 2005

    Cited by (1)

  • <no title>

    CORTOT A.

    Bull. Cancer 93, 19-26, 2006

    Cited by (1)

  • <no title>

    WYMANN M. P.

    Curr. Opin. Cell Biol. 17, 141-149, 2005

    Cited by (1)

  • <no title>

    ROMMEL C.

    Nat. Rev. Immunol. 7, 191-201, 2007

    Cited by (1)

  • <no title>

    ZHAO J. J.

    Proc. Natl. Acad. Sci. U.S.A. 103, 16296-16300, 2006

    Cited by (1)

  • <no title>

    JACKSON S. P.

    Nat. Med. 11, 507-514, 2005

    Cited by (1)

  • <no title>

    PHILLIPS W. A.

    Int. J. Cancer 118, 2644-2646, 2006

    Cited by (1)

  • <no title>

    DAN S.

    Cancer Res. 62, 1139-1147, 2002

    Cited by (1)

  • <no title>

    YAGUCHI S.

    J. Natl. Cancer Inst. 98, 545-556, 2006

    Cited by (1)

  • <no title>

    VANHAESEBROECK B

    Trends. Biochem. Sci. 30, 194-204, 2005

    DOI  Cited by (3)

  • <no title>

    LINGGI B.

    Trends Cell Biol. 16, 649-656, 2006

    DOI  Cited by (3)

  • <no title>

    STAUFFER F.

    Curr. Med. Chem. Anticancer Agents 5, 449-462, 2005

    DOI  Cited by (1)

  • <no title>

    OSAKI M

    Apoptosis 9, 667-676, 2004

    DOI  Cited by (8)

  • <no title>

    VIVANCO I

    Nat. Rev. Cancer 2, 489-501, 2002

    DOI  Cited by (26)

  • <no title>

    SAMUELS Y

    Cancer Cell 7, 561-573, 2005

    DOI  Cited by (2)

  • <no title>

    BADER AG

    Nat. Rev. Cancer 5, 921-929, 2005

    DOI  Cited by (5)

  • <no title>

    ANDERSON K. E.

    Int. J. Biochem. Cell Biol. 35, 1028-1033, 2003

    DOI  Cited by (1)

  • <no title>

    VANHAESEBROECK B

    Proc. Natl. Acad. Sci. U.S.A. 94, 4330-4335, 1997

    Cited by (2)

  • <no title>

    HU P.

    Mol. Cell Biol. 13, 7677-7688, 1993

    Cited by (3)

  • <no title>

    BI L.

    J. Biol. Chem. 274, 10963-10968, 1999

    DOI  Cited by (7)

  • <no title>

    CHANTRY D

    J. Biol. Chem. 272, 19236-19241, 1997

    Cited by (2)

  • <no title>

    RUCKLE T.

    Nat. Rev. Drug Discov. 5, 903-918, 2006

    DOI  Cited by (2)

  • <no title>

    KNIGHT ZA

    Cell 125, 733-747, 2006

    DOI  Cited by (2)

  • <no title>

    OKKENHAUG K.

    Science 297, 1031-1034, 2002

    Cited by (6)

  • <no title>

    SASAKI T.

    Science 287, 1040-1046, 2000

    DOI  Cited by (18)

  • <no title>

    HIRSCH E.

    Science 287, 1049-1053, 2000

    Cited by (16)

  • <no title>

    SHAYESTEH L.

    Nat. Genet. 21, 99-102, 1999

    Cited by (8)

  • <no title>

    MA Y. Y.

    Oncogene 19, 2739-2744, 2000

    Cited by (1)

  • <no title>

    CAMPBELL IG

    Cancer Res. 64, 7678-7681, 2004

    DOI  Cited by (4)

  • <no title>

    REDON R

    Cancer Res. 61, 4122-4129, 2001

    Cited by (4)

  • <no title>

    LEE JW

    Oncogene 24, 1477-1480, 2005

    DOI  Cited by (4)

  • <no title>

    SAAL LH

    Cancer Res. 65, 2554-2559, 2005

    DOI  Cited by (3)

  • <no title>

    LEVINE DA

    Clin. Cancer Res. 11, 2875-2878, 2005

    DOI  Cited by (2)

  • <no title>

    YAMORI T.

    Cancer Res. 59, 4042-4049, 1999

    Cited by (34)

Codes

  • NII Article ID (NAID)
    110006278417
  • NII NACSIS-CAT ID (NCID)
    AA10885497
  • Text Lang
    ENG
  • Article Type
    SHO
  • ISSN
    09186158
  • NDL Article ID
    8741651
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z53-V41
  • Data Source
    CJP  NDL  NII-ELS  J-STAGE 
Page Top